Markets:

Overview

News

Currencies

International

Treasuries

Biogen Idec (NQ:BIIB)

196.52 +1.02 (+0.52%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Biogen Idec

< Previous 1 2

...

29 30 31 32 33 34 35 36 37

...

48 49 Next >

Friday Stocks Update ↗

April 08, 2022

Royal Dutch Shell rose again on its earnings but is still at a p/e ratio of under 11x earnings.

Via Talk Markets

How Medicare 'Snuffed Out' Hope For Biogen's Controversial Alzheimer's Drug ↗

April 08, 2022

Only Medicare patients enrolled in specific studies will receive reimbursement.

Via Investor's Business Daily

Why Is Trevi Therapeutics (TRVI) Stock On the Move Today? ↗

April 08, 2022

Trevi Therapeutics (TRVI) stock is slipping on Friday but that's only after the biopharmaceutical company saw a massive rally yesterday.

Via InvestorPlace

Why Is Biogen (BIIB) Stock in the Spotlight Today? ↗

April 08, 2022

Medicare's decision not to cover the cost of the drug maker's expensive Alzheimer's drug is hitting the company's stock price today.

Via InvestorPlace

Morning Brief: Top Stories Dominating Financial Media on Friday, April 8 ↗

April 08, 2022

Reuters Blockchain-Based Online Games Like Axie Infinity Continue To Hook Users Despite Risks Blockchain-based online games like Axie Infinity, dubbed “play-to-earn,...

Via Benzinga

Bear Of The Day: Biogen ↗

April 04, 2022

Biogen’s MS revenues were $1.79 billion in the reporter quarter, including Ocrevus royalties, which declined 1% (both actual and constant currency basis) year over year.

Via Talk Markets

3 Undervalued Stocks to Buy This Week ↗

March 30, 2022

Here are the three undervalued stocks to buy this week.

Via Talk Markets

Layoffs at Bluebird Bio Highlight the Current Struggles of Biotech Picks ↗

April 08, 2022

Cash will be king in biotech picks like BLUE stock as governments slow approvals and reimbursements of new gene therapies.

Via InvestorPlace

Biogen's Alzheimer's Drug Aduhelm Medicare Coverage Restricted To Just Clinical Trials, CMS Finalizes ↗

April 08, 2022

Centers for Medicare and Medicaid Services (CMS) finalized its decision to restrict coverage for Biogen Inc's (NASDAQ:&

Via Benzinga

Keep Eyes on Momentum in the Small-Cap Index and The Biotech Space ↗

April 06, 2022

If BIIB can clear and close over roughly $212, it would confirm that price and momentum agree and show it's potentially ready for another move higher.

Via Talk Markets

Amylyx Pharmaceuticals Stock Crashes As FDA Doubts Its ALS Treatment ↗

March 28, 2022

Amylyx Pharmaceuticals could face an uphill battle for its ALS treatment this week.

Via Investor's Business Daily

Ionis-Biogen Partnered Amyotrophic Lateral Sclerosis Trial Disappoints ↗

March 28, 2022

Biogen Inc (NASDAQ: BIIB) and Ionis Pharmaceuticals Inc (NASDAQ: IONS) have

Via Benzinga

Biogen Shares Aduhelm Data In Alzheimer's Disease At 128 Weeks ↗

March 16, 2022

Via Benzinga

Biogen, Eisai Amend Their Alzheimer's Drug Marketing Pact ↗

March 15, 2022

Via Benzinga

Why I Sold Kohl’s Corporation Despite Possible Buyout Deal ↗

March 22, 2022

2022 has been a headline-packed for Kohl’s and KSS stock. But after a closer look at my portfolio grader, this is why it was time to sell.

Via InvestorPlace

Biogen, Eisai Unveil New Data On Another Alzheimer's Candidate, Lecanemab ↗

March 22, 2022

In the partnership that spawned aducanumab, Eisai Co Ltd (OTC: ESALY) and Biogen Inc (NASDAQ: BIIB) have

Via Benzinga

Biogen Says It Cracked The Alzheimer's Puzzle, But Investors May Need More Evidence ↗

March 16, 2022

Patients who received Aduhelm for over two years showed declines in two markers.

Via Investor's Business Daily

News-Filled Day ↗

March 15, 2022

The price of oil fell to below $100/oz on the prospect of lower demand from the PRC.

Via Talk Markets

The Daily Biotech Pulse: Biogen, Eisai Amend Aduhelm Agreement; Anaptys Acne Drug Flunks Midstage Study; Merck, AstraZeneca Discontinue Prostate Cancer Trial ↗

March 15, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Hopes For A Peace Accord ↗

March 14, 2022

The winner today was BioNTech up 14.89% on hopes for new sales for the Covid-19 variant.

Via Talk Markets

Biogen Posts New Updates Across its Spinraza SMA Research Program ↗

March 14, 2022

Biogen Inc (NASDAQ: BIIB) announced new data and updates from its Spinraza (nusinersen) and spinal muscular atrophy (SMA) research program, including the ASCEND, RESPOND and...

Via Benzinga

Bristol Myers, Eli Lilly And 2 Others Prove You Can Still Make Money In Medical Stocks ↗

March 11, 2022

These four medical stocks are outperforming the lousy market for health care investors.

Via Investor's Business Daily

10 Biggest Price Target Changes For Tuesday ↗

March 08, 2022

Raymond James cut the price target on Ciena Corporation (NYSE: CIEN) from $80 to $75. Ciena shares fell 10.9% to close at $58.76 on Monday. Telsey Advisory Group cut Capri...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For March 8, 2022 ↗

March 08, 2022

Upgrades According to Janney Montgomery Scott, the prior rating for Wintrust Financial Corp (NASDAQ:WTFC) was changed from Neutral to Buy. Wintrust Finl earned $1.58 in the fourth...

Via Benzinga

The Daily Biotech Pulse: Ocugen Faces Regulatory Setback, vTv CEO Quits, Biogen-Eisai Make Headway With Second Alzheimer's Antibody Treatment In Japan ↗

March 04, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Merck's Keytruda Evaluated In Combination With Microbiome Therapeutic In...

Via Benzinga

Why This Analyst Sees Roughly 20% Upside In This Large-Cap Biopharma ↗

March 03, 2022

Biogen Inc (NASDAQ: BIIB) shares are now trading notably off their all-time high of $468.55 hit on June 7, achieved on the back of Aduhelm approval. An analyst at RBC...

Via Benzinga

Expert Ratings For Biogen ↗

March 03, 2022

Within the last quarter, Biogen (NASDAQ:BIIB) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 5 7...

Via Benzinga

Biogen Has An $8 Billion Alzheimer's Opportunity — Will It Materialize? ↗

March 03, 2022

A few key things have to go right for Biogen to snag a definitive win in Alzheimer's.

Via Investor's Business Daily

10 Biggest Price Target Changes For Thursday ↗

March 03, 2022

Piper Sandler cut the price target on Bright Health Group, Inc. (NYSE: BHG) from $10 to $5. Bright Health shares rose 3.2% to $2.59 in pre-market trading.

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For March 3, 2022 ↗

March 03, 2022

Upgrades For Douglas Emmett Inc (NYSE:DEI), Evercore ISI Group upgraded the previous rating of In-Line to Outperform. For the fourth quarter, Douglas Emmett had an EPS of $0.48,...

Via Benzinga

< Previous 1 2

...

29 30 31 32 33 34 35 36 37

...

48 49 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Biogen Idec (NQ:BIIB)

Headline News about Biogen Idec

Starting at $3.75/week.

Subscribe Today